hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1 Retraction in /10.3892/or.2024.8818

He,Xin; Fan,Saijun

doi:10.3892/or.2017.6156

hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1

Retraction in: /10.3892/or.2024.8818

Authors:
- Xin He
- Saijun Fan
View Affiliations

Affiliations: Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin 300192, P.R. China
Published online on: December 15, 2017 https://doi.org/10.3892/or.2017.6156
Pages: 977-984
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radioresistance remains a major challenge in the treatment of glioma, and the response of patients to radiotherapy varies considerably. MicroRNAs (miRNAs) are involved in various biological processes. The purpose of the present study was to investigate miRNAs involved in the response to radiation in glioma cell lines. Total RNA was isolated from human glioma U251 cells 30 min after γ-ray exposure and hybridized to an miRNA chip array. miRNA expression profiles were analyzed by quantitative real-time PCR. pcDNA3/EGFP-miR-212 mimic transfection was used to verify the function of miR-212 in colony formation tests, and the effect of miR-212 overexpression on U251 cells was examined by western blot analysis of apoptosis-related proteins (Bcl-2, Bax, caspase-3 and cytochrome c). The target genes of miR-212 were predicted using bioinformatic tools including miRNA databases, and breast cancer susceptibility gene 1 (BRCA1) was selected for further confirmation by EGFP fluorescence reporter and loss- and gain-of-function assays. Of the 16 candidate miRNAs showing altered expression, five were assessed by real-time PCR; miR-212 was identified as contributing to the radioresistance of glioma cells and was shown to attenuate radiation-induced apoptosis. miR-212 negatively regulated BRCA1 expression by interacting with its 3'-untranslated region, suggesting a correlation between BRCA1 expression and radiosensitivity in glioma cells. U-118MG and SHG-44 cell lines were used to confirm these observations. The response of glioma cells to radiation involves the miR-212-mediated modulation of BRCA1 gene expression, suggesting that the miR-212/BRCA1 axis may play a potential role in the radiotherapy of gliomas.

View Figures

View References

1	Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
2	Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108:171–182. 2002. View Article : Google Scholar : PubMed/NCBI
3	Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, et al: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 284:1354–1356. 1999. View Article : Google Scholar : PubMed/NCBI
4	Narod SA and Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hu Y: BRCA1, hormone, and tissue-specific tumor suppression. Int J Biol Sci. 5:20–27. 2009. View Article : Google Scholar : PubMed/NCBI
6	Caestecker KW and Van de Walle GR: The role of BRCA1 in DNA double-strand repair: Past and present. Exp Cell Res. 319:575–587. 2013. View Article : Google Scholar : PubMed/NCBI
7	Huszno J, Budryk M, Kołosza Z and Nowara E: The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology. 85:278–282. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang C, Liu X, Wang X, Li H, Kang C, et al: MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol. 16:1341–1353. 2014. View Article : Google Scholar : PubMed/NCBI
9	Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, ; National Cancer Institute of Canada Clinical Trials Group, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lim LPLN, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
12	Tsai NP, Lin YL and Wei LN: MicroRNA mir-346 targets the 5′-untranslated region of receptor-interacting protein 140 (RIP140) mRNA and up-regulates its protein expression. Biochem J. 424:411–418. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kang HW, Wang F, Wei Q, Zhao YF, Liu M, Li X and Tang H: miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett. 586:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
14	Díaz-López A, Moreno-Bueno G and Cano A: Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res. 6:205–216. 2014.PubMed/NCBI
15	Zhao L, Bode AM, Cao Y and Dong Z: Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis. 33:2220–2227. 2012. View Article : Google Scholar : PubMed/NCBI
16	Li Y, Zhang D, Chen C, Ruan Z, Li Y and Huang Y: MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell. 23:1423–1434. 2012. View Article : Google Scholar : PubMed/NCBI
17	Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and Carinci F: MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 23:1229–1234. 2010. View Article : Google Scholar : PubMed/NCBI
18	Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, et al: Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One. 8:e697842013. View Article : Google Scholar : PubMed/NCBI
19	Jiping Z, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C, et al: MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. J Cell Biochem. 114:2666–2672. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xu L, Wang F, Xu XF, Mo WH, Xia YJ, Wan R, Wang XP and Guo CY: Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells. Med Oncol. 28 Suppl 1:S189–S196. 2011. View Article : Google Scholar : PubMed/NCBI
21	Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, Yu H, Zuo Y, Pan Z, Liu RY, et al: Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology. 145:426–436.e1-e6. 2013. View Article : Google Scholar : PubMed/NCBI
22	Walter BA, Valera VA, Pinto PA and Merino MJ: Comprehensive microRNA Profiling of Prostate Cancer. J Cancer. 4:350–357. 2013. View Article : Google Scholar : PubMed/NCBI
23	Gandellini P, Rancati T, Valdagni R and Zaffaroni N: miRNAs in tumor radiation response: Bystanders or participants? Trends Mol Med. 20:529–539. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sakaguchi M, Hisamori S, Oshima N, Sato F, Shimono Y and Sakai Y: miR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1. Mol Cancer Res. 14:354–362. 2016. View Article : Google Scholar : PubMed/NCBI
25	Jiang X, Chen X, Chen L, Ma Y, Zhou L, Qi Q, Liu Y, Zhang S, Luo J and Zhou X: Upregulation of the miR-212/132 cluster suppresses proliferation of human lung cancer cells. Oncol Rep. 33:705–712. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhou C, Smith JL and Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene. 22:2396–2404. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kan C and Zhang J: BRCA1 mutation: A predictive marker for radiation therapy? Int J Radiat Oncol Biol Phys. 93:281–293. 2015. View Article : Google Scholar : PubMed/NCBI
28	Saha J and Davis AJ: Unsolved mystery: The role of BRCA1 in DNA end-joining. J Radiat Res (Tokyo). 57 Suppl 1:i18–i24. 2016. View Article : Google Scholar
29	Bencokova Z, Pauron L, Devic C, Joubert A, Gastaldo J, Massart C, Balosso J and Foray N: Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin. J Neurooncol. 86:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
30	Boukerroucha M, Josse C, Segers K, El-Guendi S, Frères P, Jerusalem G and Bours V: BRCA1 germline mutation and glioblastoma development: Report of cases. BMC Cancer. 15:1812015. View Article : Google Scholar : PubMed/NCBI
31	Chai KM, Wang CY, Liaw HJ, Fang KM, Yang CS and Tzeng SF: Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget. 5:10901–10915. 2014. View Article : Google Scholar : PubMed/NCBI